AOCNP (ADVANCED ONCOLOGY CERTIFIED NURSE
PRACTITIONER) COMPREHENSIVE BOARD REVIEW PRACTICE
EXAM: 200 HIGH-YIELD QUESTIONS WITH CORRECT ANSWERS,
DETAILED CLINICAL RATIONALES, AND EVIDENCE-BASED
MANAGEMENT STRATEGIES COVERING CHEMOTHERAPY,
TARGETED THERAPY, IMMUNOTHERAPY, RADIATION
ONCOLOGY, ONCOLOGIC EMERGENCIES, SUPPORTIVE CARE,
AND ADVERSE EFFECT MANAGEMENT
Question 1
A patient receiving doxorubicin is at highest risk for which toxicity?
A) Nephrotoxicity
B) Cardiotoxicity
C) Pulmonary fibrosis
D) Ototoxicity
Correct Answer: B) Cardiotoxicity
Rationale: Anthracyclines like doxorubicin are dose-dependent
cardiotoxins causing cardiomyopathy and heart failure. The risk
increases with cumulative doses above 400-450 mg/m², and lifetime
cumulative doses should not exceed 550 mg/m² (450 mg/m² if prior
chest radiation). Cardiac monitoring with MUGA or echocardiogram is
required before each dose.
Question 2
Which laboratory value is most critical to check before administering
myelosuppressive chemotherapy?
,A) Platelet count
B) Serum calcium
C) Hemoglobin A1C
D) Amylase
Correct Answer: A) Platelet count
Rationale: Platelet count determines bleeding risk and safety for
chemotherapy administration. A platelet count <50,000/mm³ typically
requires dose modification or treatment delay. ANC also determines
infection risk. Both are critical pre-chemotherapy labs.
Question 3
A patient with tumor lysis syndrome is expected to have which lab
abnormality?
A) Hypercalcemia
B) Hypokalemia
C) Hyperuricemia
D) Hypoglycemia
Correct Answer: C) Hyperuricemia
Rationale: Rapid cell lysis releases purines that are metabolized to uric
acid, leading to hyperuricemia. TLS also causes hyperkalemia,
hyperphosphatemia, and secondary hypocalcemia (due to calcium
binding with phosphate). This is an oncologic emergency requiring
aggressive hydration, allopurinol or rasburicase, and close monitoring.
Question 4
A patient receiving oxaliplatin reports tingling and numbness in hands
and throat worsened by cold exposure. How should the AOCNP manage
this?
A) Grade 4 peripheral neuropathy; permanently discontinue oxaliplatin
B) Grade 1 acute neuropathy; continue therapy without dose reduction
,C) Grade 2 chronic neuropathy; reduce dose by 25%
D) Grade 3 acute neuropathy; hold oxaliplatin until resolution
Correct Answer: B) Grade 1 acute neuropathy; continue therapy
without dose reduction
Rationale: Oxaliplatin causes a unique acute cold-induced neuropathy
(pharyngolaryngeal dysesthesia) AND a chronic cumulative peripheral
neuropathy. Acute neuropathy resolves completely between cycles and
does not interfere with ADLs, so it is Grade 1. Management involves
patient education to avoid cold drinks, cold objects, and cold
environments. No dose reduction is needed for Grade 1 acute
neuropathy.
Question 5
A patient with metastatic non-small cell lung cancer (NSCLC) with an
EGFR exon 19 deletion is started on osimertinib. What is the most
critical adverse effect to educate the patient to report immediately?
A) Grade 1 diarrhea
B) Dry skin and rash
C) Shortness of breath or chest pain
D) Mild paronychia
Correct Answer: C) Shortness of breath or chest pain
Rationale: Osimertinib is a 3rd-generation EGFR-TKI. While rash and
diarrhea are common, the most critical and potentially fatal adverse
effect is Interstitial Lung Disease (ILD)/Pneumonitis, which presents as
acute shortness of breath, cough, or chest pain. Patients must seek
emergency care if these occur; the drug must be permanently
discontinued if ILD is confirmed.
Question 6
A patient with HER2-positive metastatic breast cancer is receiving
, pertuzumab, trastuzumab, and docetaxel (TCH). Why is a baseline
echocardiogram required?
A) Pertuzumab causes irreversible peripheral neuropathy
B) Docetaxel causes dose-limiting cardiotoxicity
C) Dual HER2 blockade increases risk of left ventricular dysfunction
D) Trastuzumab causes pulmonary fibrosis
Correct Answer: C) Dual HER2 blockade increases risk of left
ventricular dysfunction
Rationale: Both trastuzumab and pertuzumab can cause left ventricular
ejection fraction (LVEF) decline, and the combination (dual HER2
blockade) increases this risk significantly. A baseline echo is standard
before initiation, with regular monitoring during treatment. Docetaxel
does not cause dose-limiting cardiotoxicity; trastuzumab causes
cardiomyopathy, not fibrosis.
Question 7
A patient on cisplatin develops a sudden drop in urine output despite
adequate hydration. Which intervention is most appropriate initially?
A) Administer furosemide 40 mg IV push
B) Obtain a stat serum magnesium level
C) Check a serum creatinine and BUN, and evaluate for acute kidney
injury
D) Increase the normal saline infusion rate to 250 mL/hr
Correct Answer: C) Check a serum creatinine and BUN, and evaluate
for acute kidney injury
Rationale: Cisplatin is highly nephrotoxic. Oliguria after hydration
suggests possible acute kidney injury (AKI). The first step is to assess
renal function with labs. Furosemide is not first-line without knowing
PRACTITIONER) COMPREHENSIVE BOARD REVIEW PRACTICE
EXAM: 200 HIGH-YIELD QUESTIONS WITH CORRECT ANSWERS,
DETAILED CLINICAL RATIONALES, AND EVIDENCE-BASED
MANAGEMENT STRATEGIES COVERING CHEMOTHERAPY,
TARGETED THERAPY, IMMUNOTHERAPY, RADIATION
ONCOLOGY, ONCOLOGIC EMERGENCIES, SUPPORTIVE CARE,
AND ADVERSE EFFECT MANAGEMENT
Question 1
A patient receiving doxorubicin is at highest risk for which toxicity?
A) Nephrotoxicity
B) Cardiotoxicity
C) Pulmonary fibrosis
D) Ototoxicity
Correct Answer: B) Cardiotoxicity
Rationale: Anthracyclines like doxorubicin are dose-dependent
cardiotoxins causing cardiomyopathy and heart failure. The risk
increases with cumulative doses above 400-450 mg/m², and lifetime
cumulative doses should not exceed 550 mg/m² (450 mg/m² if prior
chest radiation). Cardiac monitoring with MUGA or echocardiogram is
required before each dose.
Question 2
Which laboratory value is most critical to check before administering
myelosuppressive chemotherapy?
,A) Platelet count
B) Serum calcium
C) Hemoglobin A1C
D) Amylase
Correct Answer: A) Platelet count
Rationale: Platelet count determines bleeding risk and safety for
chemotherapy administration. A platelet count <50,000/mm³ typically
requires dose modification or treatment delay. ANC also determines
infection risk. Both are critical pre-chemotherapy labs.
Question 3
A patient with tumor lysis syndrome is expected to have which lab
abnormality?
A) Hypercalcemia
B) Hypokalemia
C) Hyperuricemia
D) Hypoglycemia
Correct Answer: C) Hyperuricemia
Rationale: Rapid cell lysis releases purines that are metabolized to uric
acid, leading to hyperuricemia. TLS also causes hyperkalemia,
hyperphosphatemia, and secondary hypocalcemia (due to calcium
binding with phosphate). This is an oncologic emergency requiring
aggressive hydration, allopurinol or rasburicase, and close monitoring.
Question 4
A patient receiving oxaliplatin reports tingling and numbness in hands
and throat worsened by cold exposure. How should the AOCNP manage
this?
A) Grade 4 peripheral neuropathy; permanently discontinue oxaliplatin
B) Grade 1 acute neuropathy; continue therapy without dose reduction
,C) Grade 2 chronic neuropathy; reduce dose by 25%
D) Grade 3 acute neuropathy; hold oxaliplatin until resolution
Correct Answer: B) Grade 1 acute neuropathy; continue therapy
without dose reduction
Rationale: Oxaliplatin causes a unique acute cold-induced neuropathy
(pharyngolaryngeal dysesthesia) AND a chronic cumulative peripheral
neuropathy. Acute neuropathy resolves completely between cycles and
does not interfere with ADLs, so it is Grade 1. Management involves
patient education to avoid cold drinks, cold objects, and cold
environments. No dose reduction is needed for Grade 1 acute
neuropathy.
Question 5
A patient with metastatic non-small cell lung cancer (NSCLC) with an
EGFR exon 19 deletion is started on osimertinib. What is the most
critical adverse effect to educate the patient to report immediately?
A) Grade 1 diarrhea
B) Dry skin and rash
C) Shortness of breath or chest pain
D) Mild paronychia
Correct Answer: C) Shortness of breath or chest pain
Rationale: Osimertinib is a 3rd-generation EGFR-TKI. While rash and
diarrhea are common, the most critical and potentially fatal adverse
effect is Interstitial Lung Disease (ILD)/Pneumonitis, which presents as
acute shortness of breath, cough, or chest pain. Patients must seek
emergency care if these occur; the drug must be permanently
discontinued if ILD is confirmed.
Question 6
A patient with HER2-positive metastatic breast cancer is receiving
, pertuzumab, trastuzumab, and docetaxel (TCH). Why is a baseline
echocardiogram required?
A) Pertuzumab causes irreversible peripheral neuropathy
B) Docetaxel causes dose-limiting cardiotoxicity
C) Dual HER2 blockade increases risk of left ventricular dysfunction
D) Trastuzumab causes pulmonary fibrosis
Correct Answer: C) Dual HER2 blockade increases risk of left
ventricular dysfunction
Rationale: Both trastuzumab and pertuzumab can cause left ventricular
ejection fraction (LVEF) decline, and the combination (dual HER2
blockade) increases this risk significantly. A baseline echo is standard
before initiation, with regular monitoring during treatment. Docetaxel
does not cause dose-limiting cardiotoxicity; trastuzumab causes
cardiomyopathy, not fibrosis.
Question 7
A patient on cisplatin develops a sudden drop in urine output despite
adequate hydration. Which intervention is most appropriate initially?
A) Administer furosemide 40 mg IV push
B) Obtain a stat serum magnesium level
C) Check a serum creatinine and BUN, and evaluate for acute kidney
injury
D) Increase the normal saline infusion rate to 250 mL/hr
Correct Answer: C) Check a serum creatinine and BUN, and evaluate
for acute kidney injury
Rationale: Cisplatin is highly nephrotoxic. Oliguria after hydration
suggests possible acute kidney injury (AKI). The first step is to assess
renal function with labs. Furosemide is not first-line without knowing
